// App-Quantinova.ai

: An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Researchers

Presenter

  • Bogdan Muresan

Principal Investigators

  • Carla M. Mamolo

  • Joseph C Cappelleri

  • Rocco J. Crescenzo

  • Eric Leip

  • Andrea Viqueira

  • Bart Heeg

Medical Centers

  • Ingress Health, Rotterdam, Netherlands

  • Pfizer, Groton, CT

  • Pfizer Inc., Walton Oaks, United Kingdom

  • Pfizer Inc., Cambridge, MA

  • Pfizer Spain, Madrid, Spain

Locations

  • Netherlands

  • United States

  • United Kingdom

  • Spain

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Cluster of Differentiation 206

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved